Agata Różycka | Neurogenetics | Best Researcher Award

Dr. Agata Różycka | Neurogenetics | Best Researcher Award

Dr. Agata Różycka, Poznan University of Medical Sciences, Poland.

Dr. Agata Różycka is a molecular neuroscientist and university lecturer at Poznan University of Medical Sciences, specializing in the molecular biology of neurodegeneration, epilepsy, and aging. With a robust academic background that combines molecular biology and pharmacy, she brings together clinical relevance and genetic insight. Her research delves into oxidative stress, genetic polymorphisms, and signal transduction in neurological diseases, with significant contributions to personalized medicine. She is also an accomplished educator, known for delivering high-quality instruction across medical and life science programs. Her scholarly work, published in respected journals and cited widely (h-index 15), continues to impact the fields of neurobiology and molecular diagnostics.

Profile

Orcid

 

🎓 Early Academic Pursuits

Dr. Agata Różycka’s journey in science began with a strong foundation in Molecular Biology and Pharmacy, having completed her MSc and PhD at Adam Mickiewicz University and the Poznan University of Medical Sciences in Poland. From early on, her academic interests were drawn to the molecular intricacies of the brain and human physiology. Her dual institutional training provided her with a broad yet profound grasp of pharmacogenomics, neurobiology, and genetic mechanisms underpinning disease processes. Her graduate years were marked by a passion for decoding the language of DNA and understanding the cellular responses to oxidative stress and genetic variation.

🧠 Professional Endeavors in Neuroscience

Currently a University Lecturer in the Department of Biochemistry and Molecular Biology at the Poznan University of Medical Sciences, Dr. Różycka has dedicated her career to unraveling the molecular foundations of neurological disorders, particularly neurodegeneration, epilepsy, and aging-related changes. Her teaching spans key courses in biochemistry, diagnostics, molecular biology, and laboratory techniques, and she has taught across diverse departments including medicine, nutrition, and biotechnology. Her lectures are known for clarity and depth, consistently earning high evaluations from students, a reflection of her commitment to excellence in scientific education.

🧬 Contributions and Research Focus

Dr. Różycka’s research is defined by its focus on the molecular and genetic mechanisms of neurodegeneration and neurological diseases. She has explored the role of oxidative stress, genetic polymorphisms, and signal transduction pathways in brain aging and epileptogenesis. Her expertise in SNP genotyping, DNA/RNA analysis, and genotoxicity assays has positioned her as a respected figure in the field. Her groundbreaking work on the expression of neuronal nicotinic acetylcholine receptors and the effects of memantine on oxidative DNA damage in aging brains, published in the International Journal of Molecular Sciences in 2025, exemplifies her translational approach to neurodegenerative research.

🧪 Innovation in Molecular Medicine

Beyond basic neuroscience, Dr. Różycka has contributed significantly to the personalized medicine landscape. Her investigations into COMT, MAO-A, and NET gene polymorphisms have improved our understanding of neuropsychiatric conditions like Parkinson’s disease and menopausal depression. Her 2021 study on serotonin polymorphisms and their relation to postoperative pain and nausea in the Journal of Personalized Medicine reflects her interdisciplinary reach, connecting genetics, neurobiology, and clinical practice to enhance patient outcomes.

📚 Academic Influence and Impact

With 682 citations and an h-index of 15, Dr. Różycka’s body of work has earned global recognition in the neuroscientific and biomedical communities. Her contributions are actively followed on platforms such as ORCID, ResearchGate, and Academia.edu, where her network of collaborators and readers continues to grow. Through these forums, she has shaped critical discourse in molecular neuroscience and neuropharmacology, helping researchers worldwide explore new diagnostic and therapeutic frontiers.

🏆 Recognition and Mentorship

Dr. Różycka’s academic excellence extends to mentorship and community engagement. As an educator, she has inspired many budding scientists, fostering critical thinking and hands-on skills in molecular lab techniques. Her reputation for nurturing scientific curiosity and rigor among students is matched by her ability to integrate cutting-edge research into the classroom. Her enduring impact is also evident in the numerous collaborations and citations her work has garnered, reflecting both peer appreciation and scholarly relevance.

🔬 Legacy and Future Contributions

Looking forward, Dr. Różycka aims to delve deeper into epigenetic mechanisms and neuroprotective strategies in aging brains. Her future projects include investigating novel therapeutic targets within cholinergic and serotonergic pathways, with the long-term vision of contributing to early intervention in age-related cognitive decline and epilepsy. As neuroscience continues to evolve, her legacy will be marked by a rare blend of precision science, passionate teaching, and a visionary approach to human health.

Publication

  • Title: Expression of Neuronal Nicotinic Acetylcholine Receptor and Early Oxidative DNA Damage in Aging Rat Brain—The Effects of Memantine
    Authors: Małgorzata Anna Lewandowska, Agata Różycka, Teresa Grzelak, Bartosz Kempisty, Paweł Piotr Jagodziński, Margarita Lianeri, Jolanta Dorszewska
    Year: 2025

 

  • Title: Relationship of Postoperative Pain and PONV after Minimally Invasive Surgery with the Serotonin Concentrations and Receptors’ Gene Polymorphisms
    Authors: Natalia Ignaszak-Kaus, Antoni J. Duleba, Aleksandra Mrozikiewicz, Grażyna Kurzawińska, Agata Różycka, Jan Hauke, Michał Gaca, Leszek Pawelczyk, Paweł Piotr Jagodziński, Piotr Jędrzejczak
    Year: 2021

 

  • Title: Importance of polymorphic variants of phosphatidylethanolamine N-methyltransferase (PEMT) gene in the etiology of intrauterine fetal death in the Polish population
    Authors: Agnieszka Seremak-Mrozikiewicz, Magdalena Barlik, Agata Różycka, Grażyna Kurzawińska, Andrzej Klejewski, Hubert Wolski, Krzysztof Drews
    Year: 2018

 

  • Title: The MAOA, COMT, MTHFR and ESR1 gene polymorphisms are associated with the risk of depression in menopausal women
    Authors: Not fully listed, but includes Agata Różycka (complete list available in source)
    Year: 2016

🔚 Conclusion

Dr. Agata Różycka stands out as a leading figure in the intersection of molecular neuroscience and clinical genetics, with a proven track record of impactful research and dedicated teaching. Her innovative studies on aging brains, gene polymorphisms, and neurotransmitter systems not only advance scientific understanding but also bridge the gap between molecular theory and patient care. With ongoing projects focused on epigenetic regulation and neuroprotective strategies, her work promises to shape the future of neurological health and personalized therapeutics.

 

 

Izabela Małysz-Cymborska | Neurogenetics | Best Researcher Award

Assoc. Prof. Dr. Izabela Małysz-Cymborska | Neurogenetics | Best Researcher Award

Assoc. Prof. Dr. Izabela Małysz-Cymborska,  Department of Neurology and Neurosurgery, School of Medicine, University of Warmia and Mazury, Poland.

Dr. Izabela Małysz-Cymborska is a distinguished biomedical researcher and Associate Professor in Neurosurgery at the University of Warmia and Mazury, Poland. Her academic path began with a Master’s in Biology and culminated in a Ph.D. focused on hormonal mechanisms, followed by a Habilitation in Medicine. Her research spans neuroregeneration, stem cell therapy, and immunomodulatory strategies for neurological diseases such as ALS and stroke. She has led and contributed to nationally funded projects like NanoTech4ALS, Explore Me, and her current OPUS-funded investigation using a swine model for stroke therapy. Her interdisciplinary approach bridges molecular biology, reproductive science, and clinical neuroscience, demonstrating a rare ability to translate foundational research into therapeutic innovation.

Profile

Google Scholar

🎓 Early Academic Pursuits

Dr. Izabela Małysz-Cymborska embarked on her academic journey with a deep-rooted interest in biological sciences. Born on September 21, 1985, in Poland, she pursued her undergraduate studies at the University of Warmia and Mazury in Olsztyn, earning a Master of Science degree in Biology in 2009. Her passion for advanced biomedical research led her to the Institute of Animal Reproduction and Food Research of the Polish Academy of Sciences, where she completed her Ph.D. in 2015. Her doctoral research, grounded in hormonal action mechanisms, laid the foundation for her future contributions to neurobiology and regenerative medicine.

🧠 Professional Endeavors in Neuroscience

Dr. Małysz-Cymborska’s postdoctoral and professional journey has been largely rooted in neuroscientific investigation, with a special focus on neuroregeneration and stroke therapy. Since 2021, she has held the position of Associate Professor in the Department of Neurosurgery at the University of Warmia and Mazury. Her early postdoctoral fellowships (2015–2018) focused on pioneering work in the application of glial progenitors and stem cells in neurological disorders like ALS. These formative experiences not only enriched her research trajectory but also provided a vital bridge between animal studies and translational medicine.

🧪 Research Focus and Scientific Contributions

Dr. Małysz-Cymborska’s research portfolio reflects a consistent dedication to understanding complex neural pathologies and their treatment through regenerative approaches. She has led and contributed to several national and international projects, including NanoTech4ALS, which investigated MRI-monitored transplantation techniques using hydrogel carriers for ALS treatment. Her current role as Principal Investigator in the OPUS-funded project explores an endovascular model of stroke in swine, opening new therapeutic pathways for immunomodulation. She has also delved into reproductive biology, investigating the influence of gonadotropins on prostaglandin synthesis and the function of the corpus luteum, showcasing her multidisciplinary expertise.

🧬 Bridging Regeneration and Technology

A major hallmark of Dr. Małysz-Cymborska’s work is the integration of regenerative medicine and cutting-edge biomedical technologies. Her involvement in Explore Me and NanoTech4ALS demonstrated her commitment to merging cellular therapy with advanced biomaterials and imaging. These projects explored the therapeutic potential of mesenchymal stem cells and human glial progenitors for neurodegenerative conditions, reflecting her drive to push boundaries in translational medicine and neurosurgery.

🏅 Accolades and Recognition

Dr. Małysz-Cymborska’s scientific accomplishments were recognized through her Habilitation Degree in Medicine, awarded in 2022 by the University of Warmia and Mazury—a prestigious academic achievement in Poland that underscores her contributions to the medical sciences. Additionally, her appointment as the Dean’s representative for animal experiments between 2018 and 2019 further illustrates the trust and respect she commands within her institution and the research community.

🌍 Impact and Influence in Translational Neuroscience

Her work has had significant implications not only in Poland but also across the global neuroscience landscape. By focusing on models that simulate real-world human neurological disorders, such as swine models for stroke and ALS, she has established platforms that can more accurately predict treatment outcomes in humans. Her collaborative efforts within national strategic medical programs have enriched the broader field of translational neuroscience, particularly in immune response modulation and neural repair mechanisms.

🔮 Legacy and Future Contributions

As her OPUS project continues until 2025, Dr. Izabela Małysz-Cymborska is poised to deliver crucial insights into stroke immunotherapy. Her legacy lies in her ability to traverse boundaries between endocrinology, neurobiology, and regenerative therapy—crafting a unique niche that advances both fundamental science and clinical application. With a promising trajectory ahead, she is set to influence future protocols in neurovascular therapy, offering hope to patients with currently untreatable conditions.

Publication

  • Hydrogel-based scaffolds to support intrathecal stem cell transplantation as a gateway to the spinal cord: clinical needs, biomaterials, and imaging technologies
    Authors: JM Oliveira, L Carvalho, J Silva-Correia, S Vieira, M Majchrzak, …
    Year: 2018

 

  • Advances in bioinks and in vivo imaging of biomaterials for CNS applications
    Authors: EP Oliveira, I Malysz-Cymborska, D Golubczyk, L Kalkowski, …
    Year: 2019

 

  • The role of glia in canine degenerative myelopathy: relevance to human amyotrophic lateral sclerosis
    Authors: D Golubczyk, I Malysz-Cymborska, L Kalkowski, M Janowski, JR Coates, …
    Year: 2019

 

  • Methacrylated gellan gum and hyaluronic acid hydrogel blends for image-guided neurointerventions
    Authors: S Vieira, P Strymecka, L Stanaszek, J Silva-Correia, K Drela, …
    Year: 2020

 

  • MRI-guided intrathecal transplantation of hydrogel-embedded glial progenitors in large animals
    Authors: I Malysz-Cymborska, D Golubczyk, L Kalkowski, A Burczyk, M Janowski, …
    Year: 2018

 

  • Endovascular model of ischemic stroke in swine guided by real-time MRI
    Authors: D Golubczyk, L Kalkowski, J Kwiatkowska, M Zawadzki, P Holak, J Glodek, …
    Year: 2020

 

  • Expression of the vascular endothelial growth factor receptor system in porcine oviducts after induction of ovulation and superovulation
    Authors: I Małysz-Cymborska, A Andronowska
    Year: 2014

 

  • Rabbit model of human gliomas: implications for intra-arterial drug delivery
    Authors: H Qin, M Janowski, MS Pearl, I Malysz-Cymborska, S Li, CG Eberhart, …
    Year: 2017

 

  • Two in one: use of divalent manganese ions as both cross-linking and MRI contrast agent for intrathecal injection of hydrogel-embedded stem cells
    Authors: L Kalkowski, D Golubczyk, J Kwiatkowska, P Holak, K Milewska, …
    Year: 2021

 

  • Effect of hCG and eCG treatments on Prostaglandins Synthesis in the Porcine Oviduct
    Authors: I Małysz‐Cymborska, AJ Ziecik, A Waclawik, A Andronowska
    Year: 2013

 

🧾 Conclusion

Dr. Małysz-Cymborska’s career reflects a compelling fusion of scientific curiosity, clinical relevance, and academic rigor. With notable achievements in regenerative medicine and translational neuroscience, she continues to shape the future of therapeutic interventions for complex neurological disorders. Her ongoing research promises to pave the way for advanced stroke treatments and immune-based neurotherapies, cementing her role as a key contributor to modern biomedical science.

Zhenhua Wu | Neurogenetics | Distinguished Scientist Award

Dr. Zhenhua Wu | Neurogenetics | Distinguished Scientist Award

Dr. Zhenhua Wu, Exegenesis Bio, Inc ,United States.

Zhenhua Wu is a distinguished biotech entrepreneur and scientific leader with over 20 years of experience across the research and development value chain. As the founder, President, and CEO of Exegenesis Bio Inc., he has pioneered accessible, innovative gene therapies for patients with unmet medical needs. His journey spans rigorous academic beginnings, executive leadership in multiple biotechnology companies, and a steadfast commitment to global health advancement. Known for assembling world-class talent and making strategic decisions, Wu has played a key role in shaping the future of gene therapy through both scientific and business excellence.

Profile

Orcid

 

🎓 Early Academic Pursuits

Zhenhua Wu’s journey into the world of biotechnology and gene therapy was shaped by a solid academic foundation rooted in scientific rigor and innovation. During his early academic pursuits, he demonstrated a deep curiosity for biological systems and therapeutic sciences. This intellectual appetite laid the groundwork for his future endeavors in translational medicine, where scientific discovery meets real-world application. His academic training not only honed his research skills but also instilled a lifelong commitment to innovation in the life sciences.

💼 Professional Endeavors

With more than two decades of hands-on experience in the research and development value chain, Zhenhua Wu has established himself as a seasoned leader in biotechnology. He has served in executive roles across a range of biotech companies of various sizes and strategic focuses. In each capacity, he brought visionary leadership, guiding teams to deliver impactful solutions in the biomedical space. His career has been a progressive climb from scientific inquiry to corporate strategy, integrating a robust understanding of science with sharp business acumen.

🧬 Contributions and Research Focus

As a pioneer in the field of gene therapy, Zhenhua Wu’s contributions are both profound and multifaceted. He is the founder and current President and CEO of Exegenesis Bio Inc., a multinational gene therapy company based in Philadelphia, PA. Under his leadership, the company has developed a pipeline of innovative, affordable gene therapies designed to address high unmet medical needs. His research focus lies in advancing next-generation gene therapies that are not only effective but also accessible, aiming to bridge the gap between scientific breakthroughs and patient care.

🏆 Accolades and Recognition

Zhenhua Wu’s impactful career has earned him recognition as a visionary entrepreneur and scientific innovator. Though his biography remains modest in tone, his work has resonated across the biotech sector, attracting significant investment and strategic partnerships. His ability to build and lead a cutting-edge biotech company from the ground up has marked him as a key influencer in gene therapy, with accolades stemming from both industry peers and investors who recognize the value and promise of his work.

🌍 Impact and Influence

Through Exegenesis Bio, Zhenhua Wu has catalyzed a new wave of therapeutic innovation with global reach. His influence extends beyond the lab and boardroom, impacting regulatory conversations, patient advocacy movements, and international biotech development. By forging cross-continental collaborations and assembling a top-tier team of experts, he has ensured that the company is positioned as a global leader in gene therapy solutions, redefining what is possible in patient care and drug development.

🧭 Legacy and Future Contributions

Looking ahead, Zhenhua Wu continues to chart a path focused on expanding access to gene therapy on a global scale. His legacy is being built not only through the therapies under development but also through the culture of scientific integrity, innovation, and purpose that he has instilled in his company. He remains dedicated to mentoring future leaders, cultivating partnerships that push boundaries, and shaping a future where life-altering treatments are within reach for all who need them.

🧠 Visionary Leadership in Gene Therapy

At the heart of Zhenhua Wu’s professional identity is his role as a visionary leader in the fast-evolving field of gene therapy. His ability to connect scientific breakthroughs with patient-focused strategies has transformed Exegenesis Bio into a beacon of hope for countless individuals suffering from genetic diseases. Through his relentless pursuit of innovation, ethical leadership, and commitment to excellence, he continues to redefine what leadership means in the life sciences industry.

Publication

  • Title: Tunneling Nanotubes and Gap Junctions–Their Role in Long-Range Intercellular Communication during Development, Health, and Disease Conditions
    Authors: Ariazi J, Benowitz A, De Biasi V, den Boer M, Cherqui S, Cui H, Douillet N, Eugenin EA, Favre D, Goodman S, et al.
    Year: 2017

 

  • Title: Quantitative assessment of Aβ peptide in brain, cerebrospinal fluid and plasma following oral administration of γ-secretase inhibitor MRK-560 in rats
    Authors: Wu G, Wu Z, Na S, Hershey JC
    Year: 2015

 

  • Title: Role of the MEOX2 homeobox gene in neurovascular dysfunction in Alzheimer disease
    Authors: Wu Z, Guo H, Chow N, Sallstrom J, Bell RD, Deane R, Brooks AI, Kanagala S, Rubio A, Sagare A, et al.
    Year: 2005

 

🔚 Conclusion

Zhenhua Wu’s career reflects the powerful intersection of science, leadership, and purpose. From building a visionary biotech enterprise to steering the development of transformative therapies, his contributions continue to resonate across the scientific community and healthcare industry. His legacy is not only defined by the innovations he leads today but also by the future he is helping shape—one where advanced gene therapies are more equitable, effective, and globally impactful. Through unwavering dedication and strategic foresight, he stands as a beacon of inspiration in the world of modern biotechnology.